Page 38 - ESGO - Vulvar cancer - Complete report_fxd2

Table 9. Original studies presenting response and survival data in patients treated with primary chemo

Authorreference Year N Chemotherapy regimen Radiothe

Moore et al.a,226 2012 LAVC: N = 58 Weekly CisP 40 mg/m² IV, up to 7 cycles 57.6 Gy in

Landrum et al.224 2008 LAVC: N = 33 Either weekly CisP 40 mg/m² or two cycles of 47.6 Gy in
Mak et al.231 2011 LAVC : N = 24 CiSP 50 mg/m² IV d1 + 5-FU 1,000 mg/m² IV d1-
4

Either weekly CisP or 3-4 week 5-FU based 50 Gy, timi
regimens

Leiserowitz et al.232 1997 LAVC : N = 23 5-FU 1,000 mg/m² infusion d1-4 + CisP 100 Vulvar and
mg/m² IV d2, given 2-3 times during radiotherapy 1.8 Gy BID

Tans et al.228 2011 LAVC : N = 20 5-FU 1,000 mg/m² infusion d1-4 + MMC 10 Split cours
Wahlen et al.234 1995 LAVC : N = 19 mg/m² IV d1, given first week of each course of fractions w
Russel et al.229 1992 LAVC: N = 18 radiotherpay

5-FU 1,000 mg/m² infusion d1-4 given weeks 1 + 45-50 Gy
5 of radiotherapy. Six pts also given MMC 10 implant or
mg/m² IV d1

5-FU 750-1,000 mg/m² infusion d1-4 + CisP 100 54 Gy fo

mg/m² IV d1, 2-3 cycles given microscopi

Sebag-Montefiore et al.227 1994 LAVC: N = 16 5-FU 750 mg/m² infusion d1–5 + MMC 10 mg/m2 45 Gy in 2-
IV d1, given first 5 d and last 5 d of radiotherapy

Koh et al.233 1993 LAVC: N = 14 5-FU 750-1,000 mg/m² IV infusion d1-4, weekly 54 Gy in ei
for 3 cycles

Cunningham et al.235 1997 LAVC : N = 14 5-FU 1000 mg/m² infusion d1-4 + CisP 50 mg/m² 45-50 Gy p
d1, given on first and last week of radiotherapy

Iversen et al.238 1982 LAVC: N = 9 Bleo 30 mg IM d 1, 3, 5 repeated after 2 weeks 36-40 Gy i
Recur.: N =4

a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, b treatment response among the 34 patients treated
specifically), 5-FU: 5-fluorouracil, cCR: clinical complete response, CR: complete response, CisP: cisplatin, Gy: Gray, LAV
of disease and no recurrence, pCR: pathologic complete response, PR: partial response, Recurr.: recurrence.

 VULVAR CANCE
38